University of Utah / Huntsman Cancer Institute
Contributions
Type: Publication Only
Background
Most patients with Multiple Myeloma (MM) will relapse after an initial response and eventually succumb to their disease. This is due to the persistence of chemotherapy-resistant tumor cells in the patients’ bone marrow (BM) and immunotherapeutic approaches could contribute to eradicating these remaining cells. We evaluated SLLP1 as a potential immunotherapeutic target for MM.
Aims
Our goal was to evaluate cancer-testis antigen SLLP1 as a potential target for the immunotherapy of Multiple Myeloma.
Methods
We determined SLLP1 expression in myeloma cell lines and 394 BM samples from myeloma patients (n=177) and BM samples from healthy donors (n=11). 896 blood samples and 64 BM samples from myeloma patients (n=263) and blood from healthy donors (n=112) were analyzed for anti-SLLP1 antibodies. Seropositive patients were evaluated regarding SLLP1-specific T cells.
Results
Most cell lines showed SLLP1 RNA and protein expression while it was absent from normal BM. Of 177 patients 41% evidenced SLLP1 expression at least once during the course of their disease and 44% of newly diagnosed patients were SLLP1-positive. Expression of SLLP1 was associated with adverse cytogenetics and with negative prognostic factors including the patient’s age, number of BM-infiltrating plasma cells, serum albumin, β2-microglobulin, creatinine, and hemoglobin. Among patients treated with allogeneic stem cell transplantation those with SLLP1 expression showed a trend towards a reduced overall survival. Spontaneous anti-SLLP humoral immunity was detectable in 9.5% of patients but none of the seropositive patients evidenced SLLP1-specific T cells. However, antigen-specific T cells could readily be induced in vitro after stimulation with SLLP1.
Summary
SLLP1 represents a promising target for the immunotherapy of MM, in particular for the adoptive transfer of T cell receptor-transduced T cells.
Keyword(s): Adoptive immunotherapy, Antigen-specific T cells, Immunotherapy, Multiple myeloma
Session topic: Publication Only
Type: Publication Only
Background
Most patients with Multiple Myeloma (MM) will relapse after an initial response and eventually succumb to their disease. This is due to the persistence of chemotherapy-resistant tumor cells in the patients’ bone marrow (BM) and immunotherapeutic approaches could contribute to eradicating these remaining cells. We evaluated SLLP1 as a potential immunotherapeutic target for MM.
Aims
Our goal was to evaluate cancer-testis antigen SLLP1 as a potential target for the immunotherapy of Multiple Myeloma.
Methods
We determined SLLP1 expression in myeloma cell lines and 394 BM samples from myeloma patients (n=177) and BM samples from healthy donors (n=11). 896 blood samples and 64 BM samples from myeloma patients (n=263) and blood from healthy donors (n=112) were analyzed for anti-SLLP1 antibodies. Seropositive patients were evaluated regarding SLLP1-specific T cells.
Results
Most cell lines showed SLLP1 RNA and protein expression while it was absent from normal BM. Of 177 patients 41% evidenced SLLP1 expression at least once during the course of their disease and 44% of newly diagnosed patients were SLLP1-positive. Expression of SLLP1 was associated with adverse cytogenetics and with negative prognostic factors including the patient’s age, number of BM-infiltrating plasma cells, serum albumin, β2-microglobulin, creatinine, and hemoglobin. Among patients treated with allogeneic stem cell transplantation those with SLLP1 expression showed a trend towards a reduced overall survival. Spontaneous anti-SLLP humoral immunity was detectable in 9.5% of patients but none of the seropositive patients evidenced SLLP1-specific T cells. However, antigen-specific T cells could readily be induced in vitro after stimulation with SLLP1.
Summary
SLLP1 represents a promising target for the immunotherapy of MM, in particular for the adoptive transfer of T cell receptor-transduced T cells.
Keyword(s): Adoptive immunotherapy, Antigen-specific T cells, Immunotherapy, Multiple myeloma
Session topic: Publication Only